Neoplasms

Nervous System Diseases

All Conditions

Brain Neoplasms

Epilepsy

Brain Diseases

Central Nervous System Diseases

Central Nervous System Neoplasms

Nervous System Neoplasms

Channel Blockers

Anticonvulsants

All Drugs and Chemicals

Lacosamide

Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.

UCB Cares

This study is being conducted to find out whether lacosamide (a drug to treat epilepsy) is effective in routine clinical practice for patients with epilepsy caused by a brain tumor.

Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

A Noninterventional Study of Vimpat® (Lacosamide) as Adjunctive Antiepileptic Drug Therapy in Patients With Brain Tumor-related Epilepsy

A responder is a patient experiencing a 50 % or greater reduction in partial onset seizure frequency from Visit 1 (Baseline) to Visit 3 (Month 6 or end of Observation Period)

The Patient Global Impression of Change scale is a seven-point scale for patients to rate their general health status at the end of the study compared to how they felt before entering the study. Scores 1 to 3 mean improvement, score 4 means no change, and scores 5 to 7 mean worsening.

The category 'Improved' represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

The category 'Worsened' represents the sum of Minimally Worse, Much Worse, and Very Much Worse.

The retention rate was defined as the percentage of patients remaining in the study and on Lacosamide treatment for 6 months (6 month retention rate).

Time between first dose of LCM to discontinuation of LCM treatment was measured in days.

EQ-5D-5L: 5 Level EuroQol-5 Dimension Quality of Life Assessment is a patient-completed questionnaire for patients to rate their quality of life status in five questions and a 0 (no pain) - 100 (worst pain) score vertical visual analogue scale. The Change from Baseline is calculated for this endpoint, negative values indicate improvement and positive values indicate worsening.

EQ-5D-5L: 5 Level EuroQol-5 descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels for each dimension: no problems, slight problems, moderate problems, severe problems and extreme problems. This 5-dimension health status is converted into a numerical utility value using the UK value set, as per EuroQOL guidelines. The utility score ranges from 0 to 1 (0=worst imaginable health state, 1=best imaginable health state). The Change from Baseline is calculated for this endpoint, negative values indicate worsening and positive values indicate improvement.

MDASI-BT is a 2-part patient completed questionnaire where patients have to answer 22 questions about their brain tumor-related symptoms and 6 questions about how these symptoms interfere with their life. The mean core symptom severity is derived as the mean of the 13 core symptom items, the mean module symptom severity is derived as the mean of the 9 brain tumor specific symptom items and the mean total symptom severity is derived as the mean of all 22 symptom items. The mean interference is derived as the mean of the 6 interference items. For each score, at least 50% of the items needs to be answered for the score to be calculated. Mean core, mean module and mean total symptom severity scores are ranging from 0 to 10 (0=not present 10=as bad as you can imagine). Mean interference score is ranging from 0 to 10 (0= did not interfere 10= interfered completely). The Change from Baseline is calculated, negative values indicate improvement, positive values indicate worsening.

The actual change in seizure frequency from Baseline to Month 6 is calculated as the seizure frequency at Month 6 minus the seizure frequence at Baseline.

The seizure frequency at each time point is calculated as number of seizures per 28 days.

The percentage change from Baseline to Month 6 in seizure frequency is the actual change in seizure frequency for this period compared to the Baseline seizure frequency, which is considered 100 %.

Percentage of patients achieving a seizure-free status at the end of the 6-month Observation Period.

Discontinuation rate due to ADRs is the number of patients that discontinued from the study and from LCM treatment due to ADRs during the 6 months of observation.

Discontinuation rate due to lack of effectiveness is the number of patients that discontinued from the study and from LCM treatment due to lack of effectiveness during the 6 months of observation.

The Clinical Global Impression of Change is a seven-point scale for the treating physician to rate the patient's general health status at the end of the study compared to how the patient felt before entering the study. Scores 1 to 3 mean improvement, score 4 means no change, and scores 5 to 7 mean worsening.

The category 'Improved' represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

The category 'Worsened' represents the sum of Minimally Worse, Much Worse, and Very Much Worse.

PRA Health Sciences

UCB BIOSCIENCES GmbH

Patients with BTRE, secondary to low-grade glioma (WHO Grade 1 to 2) and with at least 1 partial-onset seizure in the 8 weeks prior to start of LCM treatment, routinely treated with lacosamide as add on to one or two baseline AEDs and who were included in the SS.

Lacosamide (SS)

Patients with brain tumor-related epilepsy (BTRE), secondary to low-grade glioma (WHO Grade 1 to 2) and with at least 1 partial-onset seizure in the 8 weeks prior to start of lacosamide (LCM) treatment, routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs (AEDs) and who were included in the Safety Set (SS).

Age, Categorical

Age, Continuous

Sex: Female, Male

Race and Ethnicity were not collected from any participant.

Race and Ethnicity Not Collected

The Baseline Characteristics refer to the Safety Set (SS), which was defined as all patients included in the study receiving treatment with LCM at least once in the study.

Patients with BTRE, secondary to low-grade glioma (WHO Grade 1 to 2) and with at least 1 partial-onset seizure in the 8 weeks prior to start of LCM treatment, routinely treated with lacosamide as add on to one or two baseline AEDs and who were included in the Full Analysis Set (FAS), having at least one post-Baseline Patient Global Impression of Change or seizure assessment.

Lacosamide (FAS)

The analysis was performed on the Full Analysis Set (FAS), which included all patients in the Safety Set (SS) who had at least 1 post Baseline Patient Global Impression of Change (PGIC) or seizure assessment.

Percentage of Patients With Response at the End of the 6-month Observation Period

Patient Global Impression of Change (PGIC) Rating at Visit 3

The retention rate was derived using Kaplan-Meier methodology where patients who completed the study were censored at the date of last administration of LCM in the study.

The analysis was performed on the Safety Set (SS), which included all patients who received treatment with lacosamide (LCM) at least once in the study.

Percentage of Patients With Retention on Lacosamide (LCM) at the End of the 6-month Observation Period

Time to Discontinuation of Lacosamide (LCM) Treatment From the Date of First Dose of LCM

Change From Visit 1 (Baseline) to Visit 3 (Month 6 or End of Observation Period) in the 5 Level EuroQol-5 Dimension Quality of Life Assessment (EQ-5D-5L) Visual Analogue Scale (VAS) Score

Change From Visit 1 (Baseline) to Visit 3 (Month 6 or End of Observation Period) in the 5 Level EuroQol-5 Dimension Quality of Life Assessment (EQ-5D-5L) Change in Utility as Converted From the 5 Dimensions

Spots Global Cancer Trial Database for Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial